Semaglutide and Cancer

New study suggests Ozempic and Wegovy may reduce cancer risk in patients with obesity

Irish researchers report in Obesity a connection between GLP-1s -the main component of Ozempic and Wegovy – restored natural killer cell function in people with obesity. Natural killer cells battle invaders such as cancer cells, which means increasing their ability to function could help people with adipose tissue more effectively fight off cancer.

Read more in Fierce Biotech

Related News